Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis

Questcor Pharmaceuticals, Inc.

today announced that the company will be teaming up with The Myositis Association (TMA) to support research and educational initiatives in dermatomyositis and polymyositis. "Questcor is very pleased to be able to make this commitment to The Myositis Association and the dermatomyositis and polymyositis communities," said Steve Cartt, Chief Operating Officer of Questcor. "Further research into these rare autoimmune disorders is imperative and we feel very strongly about supporting initiatives to increase patient education and advance the knowledge and treatment of dermatomyositis and polymyositis." Mr. Cartt added, "Acthar® is an emerging, FDA-approved treatment alternative for patients suffering from dermatomyositis and polymyositis. We believe that it is our responsibility to support the community through the funding of such initiatives and to make patients and their physicians aware of this important treatment option." Questcor pledged $25,000 to fund research grants and fellowships through The Myositis Association in 2012. In addition, the Company will be attending TMA's annual conference this week in Orlando. "Rare conditions like dermatomyositis and polymyositis often suffer from a lack of funding for basic research and education," said Bob Goldberg, Executive Director of The Myositis Association.  "That's why we are so pleased that